Abstract: The present invention relates to the provision of immunogenic or vaccine compositions comprising at least one recombinant Zika virus antigen, wherein the at least one recombinant Zika virus antigen is encoded by at least one nucleic acid sequence encoding at least one E-protein of a Zika virus or a functional fragment thereof. Further provided are nucleic acid molecules and a recombinant chimeric virus encoding and/or comprising selected antigens from a Zika virus, which are suitable as vaccine compositions. Preferably, the sequences encoding at least one Zika virus antigens suitable for eliciting an immune response are operably linked to a non-flavivirus derived vector backbone. Further provided are methods for purifying the recombinant chimeric virus particles or the immunogenic composition. Finally, there is provided an immunogenic/vaccine composition for use in a method of preventing or treating a Zika virus disease.
Type:
Grant
Filed:
December 23, 2016
Date of Patent:
September 7, 2021
Assignee:
THEMIS BIOSCIENCE GMBH
Inventors:
Erich Tauber, Sabrina Schrauf, Matthias Müllner, Katrin Ramsauer, Angelika Irmler, Patrick Csar
Abstract: The present invention provides purification strategies for sterically demanding, i.e. large and pleomorphic, infectious virus particles or VLPs derived therefrom, preferably having a measles virus scaffold to yield fractions or compositions with a significantly reduced content of contaminating host cell DNA and a reduced content of further process-related impurities. Further provided are methods of propagating and purifying infectious virus particles having a measles virus scaffold suitable to provide a preparation having a strongly reduced content of contaminating host cell DNA and a reduced content of further process-related impurities for immunogenic or anti-tumor purposes. In addition, immunogenic and vaccine compositions based on the above methods are provided. Finally, there are provided immunogenic or vaccine compositions produced by the disclosed methods, which are suitable for use in immunogenic or prophylactic vaccination treatment of a subject in need thereof.
Type:
Grant
Filed:
December 23, 2016
Date of Patent:
January 19, 2021
Assignee:
THEMIS BIOSCIENCE GMBH
Inventors:
Matthias Müllner, Erich Tauber, Patrick Csar, Angelika Irmler, Katrin Ramsauer, Sabrina Schrauf
Abstract: The invention relates to recombinant Measles virus expressing Chikungunya virus polypeptides, and concerns in particular virus like particles (VLP) that contain envelope and capsid proteins of a Chikungunya virus at their surface. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Chikungunya virus.
Type:
Grant
Filed:
September 26, 2013
Date of Patent:
May 23, 2017
Assignees:
INSTITUT PASTEUR, THEMIS BIOSCIENCE GMBH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Frederic Tangy, Samantha Brandler, Philippe Despres, Andre Habel